Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: Not quite ready for prime time

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2426-2427

  Shepherd, Frances A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PANITUMUMAB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; COLORECTAL CANCER; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; METASTASIS; NOTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 45149120506     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.4286     Document Type: Editorial

References (14)

1. Wheatley-Price P, Shepherd FA: Epidermal growth factor receptor inhibitors in the treatment lung cancer: Reality and hopes. Curr Opin Oncol 20:162-175, 2008
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
3. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
4. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
5. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
6. Sakurada A, Shepherd FA, Tsao MS: Epidermal growth factor tyrosine kinase inhibitors in lung cancer: Impact of primary or secondary mutations. Clin Lung Cancer 7:S138-S144, 2006 (suppl 4)
7. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
8. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042, 2006
9. Sequist LV, Martins GM, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449, 2008
10. Aviel-Ronen S, Blackhall FH, Shepherd FA, et al: K-ras mutations in non-small-cell lung carcinoma: A review. Clin Lung Cancer 8:30-38, 2006
11. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
12. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
13. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
14. Freeman D, Juan T, Meropol NJ, et al: Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. European Journal of Cancer Supplements 5:8, 2007 (abstr 3014; LBA 7)